Results 111 to 120 of about 255,779 (244)

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. [PDF]

, 2019
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and ...
Le, Catherine T, Murphy, William J
core   +1 more source

Biodegradable Carbonate Nanogels Loaded with Anti MFAP‐5 siRNA for Anti‐stromal Therapy of Hepatocellular Carcinoma

Advanced Science, EarlyView.
Polycarbonate nanogels enable lipid‐free delivery of anti‐MFAP‐5 siRNA into cancer‐associated fibroblasts (CAF) in hepatocellular carcinoma. In a cirrhotic murine model, this approach silences MFAP‐5, reduces fibroblast activation, and suppresses tumor growth by inhibiting NOTCH/Hes1‐driven angiogenesis. CAF‐targeted MFAP‐5 RNAi and conserved signaling
Paul Schneider, Alexander Fuchs, Michael Fichter, Vanessa Bolduan, Jenny Schunke, Özlem Akilli, Nádia C. Correia, Yannick Ehlers, Christian Czysch, Pia Winterwerber, Eliana Stanganello, Barbara Schrörs, Mustafa Diken, Christoph Eckert, Shusruto Rishik, Andreas Keller, Jörn M. Schattenberg, Stephan Grabbe, Matthias Bros, Lutz Nuhn, Leonard Kaps   +20 more
wiley   +1 more source

GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer

Heliyon
The programmed death-ligand 1 (PD-L1) on the surface of tumor cells binds to the receptor programmed cell death protein 1 (PD-1) on effector T cells, thereby inhibiting the anti-tumor immune response. Immune checkpoint blockade (ICB) therapy targeting PD-
Xue Sun, Mingen Lin, Ziyin Tian, Yan Ma, Lei Lv   +4 more
doaj   +1 more source

PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+cytotoxic T cells [PDF]

, 2017
Background. Activated infiltrating T cells play a crucial role in nephritic inflammation via the direct interaction with proximal tubular epithelial cells (TEC). Under inflammatory conditions, major histocompatibility complex class I and II molecules are
Starke, Astrid, Waeckerle-Men, Ying, Wüthrich, Rudolf P.   +2 more
core  

Redefining Dendritic Cell Vaccines: Synergistically Co‐priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines

Advanced Science, EarlyView.
Dendritic cells (DC) vaccine is an important type of vaccines. However, the limited efficacy of DC vaccines hinders their widely application. This study redefines DC vaccines and provides a new DC‐BC vaccine that have much better therapeutic efficacy.
Xiangxiang Xu, Xianlan Chen, Jin Wang, Yuhan Liu, Sidra Mustafa, Lu Diao, Rongrong Zhao, Haiyang Chi, Kang Hu, Jiashan Zhu, Jun Zhao, Mi Liu   +11 more
wiley   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source

B4GALNT4‐Mediated Glycosylation of PDK1 Activates the PI3K‐AKT Signaling Pathway to Promote Prostate Cancer Progression

Advanced Science, EarlyView.
This study identifies B4GALNT4 as a key driver of prostate cancer (PCa). It shows that B4GALNT4 glycosylates PDK1 protein at the N531 site, which stabilizes the PDK1 and constitutively activates the PI3K‐AKT pathway. This mechanism promotes tumor cell proliferation, migration, and invasion. The findings establish the B4GALNT4‐PDK1 glycosylation axis as
Shaoqin Jiang, Mengqiang Li, Qingfu Su, Ruiling Dou, Shaoshan Lin, Jili Zhang, Xiaochen Sun, Haolan Yu, Wei Bao, Min Qu, Yan Wang, Chenghua Yang, Xu Gao   +12 more
wiley   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system

OncoImmunology, 2019
We investigated the clinicopathological role of the PD-1/PD-L1 pathway in primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL) arising in the immune-privileged site.
Sehui Kim, Soo Jeong Nam, Changhee Park, Dohee Kwon, Jeemin Yim, Seung Geun Song, Chan-Young Ock, Young A Kim, Sung Hye Park, Tae Min Kim, Yoon Kyung Jeon   +10 more
doaj   +1 more source

The Expression and Biological Significance of PD-L1 on Lung Cancer Cell Lines [PDF]

, 2009
Background and objective Tumor-associated PD-L1 expression was recently shown to promote T-cell apoptosis and proposed as a potential mechanism of immune evasion by tumors. On the basis of the ability of tumor-associated PD-L1 to mediate activated T-cell
Cheng CHEN, Chuanyong MU, Jian’an HUANG, Jing SUN, Qiuxia QU, Xueguang ZHANG, Yibei ZHU   +6 more
core